Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials

$3,495.00

The Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2020
Number of pages
300+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2105

The Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in biomarker partnering deals
  • Biomarker partnering agreement structure
  • Biomarker partnering contract documents
  • Top biomarker deals by value
  • Most active biomarker dealmakers

 

The Global Biomarker Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

 

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

 

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

 

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

 

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

 

One of the key highlights of the report is that over 450 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all Biomarker partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual Biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of Biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biomarker dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Biomarker deals since 2014. Deals are listed by headline value, signed by big pharma, most active Biomarker dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biomarker dealmaking with a brief summary followed by a comprehensive listing of Biomarker deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2014. The chapter is organized by specific Biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by Biomarker partnering company A-Z, deal type definitions and Biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Biomarker partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biomarker technologies and products.

 

Key benefits

 

Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financial provides the reader with the following key benefits:

 

  • In-depth understanding of biomarker deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of biomarker agreements with numerous real life case studies
  • Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
  • Access to most active biomarker dealmakers since 2014
  • Insight into the terms included in a biomarker agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

 

Biomarker Partnering Terms and Agreements includes:

 

  • Trends in biomarker dealmaking in the biopharma industry since 2014
  • Analysis of biomarker deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life biomarker deals
  • Access to biomarker contract documents
  • The leading biomarker deals by value since 2014
  • Most active biomarker dealmakers since 2014
  • The leading biomarker partnering resources

 

In Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Biomarker Partnering terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 450 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise biomarker rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Biomarker Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of biomarker deal trends since 2014
  • Analysis of the structure of biomarker agreements with numerous real life case studies
  • Comprehensive access to over 450 actual biomarker deals entered into by the world’s biopharma companies, together with real world clause examples
  • Access to headline, upfront, milestone and royalty data
  • Full listing of biomarker deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading biomarker deals by value since 2014
  • Identify the most active biomarker dealmakers since 2014
  • Detailed access to actual biomarker deals and contracts enter into by the leading fifty big pharma companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Biomarker dealmaking

 

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Most active Biomarker dealmakers
2.4. Biomarker partnering by deal type
2.5. Biomarker partnering by therapy area
2.6. Deal terms for Biomarker partnering
2.6.1 Biomarker partnering headline values
2.6.2 Biomarker deal upfront payments
2.6.3 Biomarker deal milestone payments
2.6.4 Biomarker royalty rates

 

Chapter 3 – Leading Biomarker deals

 

3.1. Introduction
3.2. Top Biomarker deals by value

 

Chapter 4 – Most active Biomarker dealmakers

 

4.1. Introduction
4.2. Most active Biomarker dealmakers
4.3. Most active Biomarker partnering company profiles

 

Chapter 5 – Biomarker contracts dealmaking directory

 

5.1. Introduction
5.2. Biomarker contracts dealmaking directory

 

Chapter 6 – Biomarker dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Biomarker deals by company A-Z

 

Appendix 2 – Biomarker deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Biomarker deals by deal type

 

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

 

Appendix 4 – Biomarker deals by therapy area

 

Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Pediatrics
Psychiatry
Respiratory

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Biomarker partnering since 2014
Figure 2: Active Biomarker dealmaking activity since 2014
Figure 3: Biomarker partnering by deal type since 2014
Figure 4: Biomarker partnering by disease type since 2014
Figure 5: Biomarker deals with a headline value
Figure 6: Biomarker deals with an upfront value
Figure 7: Biomarker deals with a milestone value
Figure 8: Biomarker deals with a royalty rate value
Figure 9: Top Biomarker deals by value since 2014
Figure 10: Most active Biomarker dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Pharma, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, Abbott Laboratories, Abbvie, Abcodia, Abramson Cancer Center, Academic Medical Center, Accelerate Diagnostics, Accu Reference Medical Laboratory, AC Immune, Acumen Pharmaceuticals, Adaptive Biotechnologies, Adarza BioSystems, ADC Therapeutics, Aelan Cell Technologies, Aerocrine, AFFiRiS, Affymetrix, Age Labs, Agendia, Air Force Research Laboratory, AIT Laboratories, Akers Biosciences, Akili Interactive Labs, Akoya Biosciences, Albert Einstein College of Medicine, Alector, Alion Pharmaceuticals, Almac Diagnostics, ALS Association, ALS Finding a Cure Foundation, Alzeca Biosciences, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimers Research UK, Amarantus BioSciences, Amarna Therapeutics, Ambiopharm, American Association for Cancer Research, American Association of Neuromuscular & Electrodiagnostic Medicine, American Diabetes Association, Amgen, AMRA, Anavex Life Sciences, Apogenix, Applied DNA Sciences, Arbor Biosciences, Arbor Biotechnologies, Arcis Biotechnology, Arcus Biosciences, AroCell, Arrow Diagnostics, Artialis, Ascenion, Assistance Publique-Hôpitaux de Paris, Association for Frontotemporal Degeneration, Astellas Pharma, Asterand Bioscience, Asthma UK, AstraZeneca, Astute Medical, Asuragen, Aural Analytics, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), Austrian Institute of Technology, Autifony Therapeutics, Avera Heart Hospital of South Dakota, Aviana Molecular Technologies, Ayasdi, AyoxxA Biosystems, Banyan Biomarkers, Baxter International, Bayer, Bayer Healthcare, Baylor College of Medicine, Beijing InnoCare Pharma, Berg, Bertin Pharma, Beth Israel Deaconess Medical Center, BGI Tech Solutions, Bill and Melinda Gates Foundation, Bio-Techne, BioArctic Neuroscience, Biocartis, Biocept, Biodesix, BioDiscovery, Biogen, Biognosys, BioLum Sciences, BioMarker Strategies, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), bioMerieux, BiomX, BioPorto, Biopsy Sciences, Biosearch Technologies, Biothera, BioTheranostics, BioVendor, Bird Foundation, Blackfynn, BlackThorn Therapeutics, Blinktbi, BluePen Biomarkers, Blueprint Medicines, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Brain Biomarker Solutions in Gothenburg, BrainScope, Breath Diagnostics, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Buck Institute for Age Research, C2N Diagnostics, Cachet Pharma, California Stem Cell, Cambridge Epigenetix, Cambridge Isotope Laboratories, CANbridge Life Sciences, Cancer Genetics, Cancer Immunotherapy Trials Network, Cancer Research Institute, Cancer Research UK, Caprion Biosciences, Caprion Proteomics, Caraway Therapeutics, Caris Life Sciences, Carmentix, Carolinas Medical Center (CMC), Case Western Reserve University, CASI Pharmaceuticals, Catalyn Medical Technologies, Catholic University Leuven, CBD Solutions, Cedars-Sinai Medical Center, Celgene, Cellgen Diagnostics, Celmatix, Celsee, Celsius Therapeutics, Cenix BioScience, Center for Biomarker Research in Medicine, Center for Human Immunology, Autoimmunity and Inflammation, Centers for Disease Control and Prevention, Centre for Drug Research and Development (CDRD), Centre for Imaging Technology Commercialization, Centre Hospital University - Bordeaux, Centre Leon Berard, Centre National de la Recherche Scientifique, Certis, Cerveau Technologies, CHDI Foundation, Chembio Diagnostics, Children's Hospital Boston, Children's Medical Research Institute, Children's Research Institute, Children’s Hospital Colorado, Christian Doppler Research Association, Cicero Diagnostics, Cincinnati Children’s Hospital Medical Center, Circulogene, City of Hope, Cleveland Clinic, Cleveland HeartLab, Clinical Genomics, Cloud Pharmaceuticals, Cognition Therapeutics, Cohen Veterans Bioscience, Columbia University, COPD Foundation, CoreBiome, Cornell University, Covance, CRC Health, Critical Diagnostics, Crohn's and Colitis Foundation of America, Crossbeta Biosciences, CSIRO, Curetis, Curie-Cancer, Curis, Cypher Genomics, Cytox, Daiichi Sankyo, Dako, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DarwinHealth, Defense Advanced Research Projects Agency, Definiens, Department of Defense, Department of Veterans Affairs, DestiNA Genomics, Devicor Medical Products, DiaCarta, diaDexus, DiagnoCure, DiamiR, DNA Software, DNA Therapeutics, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University Medical Center, DZNE German Center for Neurodegenerative Diseases, e-NIOS, Eccrine Systems, Edith Cowan University (ECU), Eisai, Eleven Biotherapeutics, Eli Lilly, EMD Millipore, EMD Serono, Enigma Biomedical, Enterome Bioscience, Entia Biosciences, Epicore Biosystems, Epic Sciences, Epigenomics, Epinomics, Eureka Eurostars, European Commission, European Organization for Research and Treatment of Cancer, European Union, Eutropics Pharmaceuticals, Evogen, Exact Sciences, Excelra, Exosome Diagnostics, Exosome Sciences, Expesicor, Expression Analysis, Ezose Sciences, F-Star Alpha, Feinstein Institute for Medical Research, Flagship Biosciences, Flemish agency for Innovation by Science and Technology, Fluidigm, Fluofarma, Fluxion Biosciences, Food and Drug Administration (FDA), FORMA Therapeutics, Fortified Provider Network, Fosun Pharmaceutical, Foundation for Innovative New Diagnostics, Foundation for the National Institutes of Health (FNIH), Foundation Medicine, Fred Hutchinson Cancer Research Center, Freenome, Frontage Laboratories, Fudan University, G1 Therapeutics, Gallus Biopharmaceuticals, GC Pharma, Gen-Probe, GeneCentric Therapeutics, GeneNews, Genentech, General Electric (GE), Genetron Health, Geneva Foundation, Genomeon, Genomic Testing Cooperative, Genprex, GenTegra, Gentris, George Mason University, Georgetown University, Georgetown University Hospital, George Washington University, Gilead Sciences, GlaxoSmithKline, Global Discovery Biosciences, Global Genomics Group, Gloval Specimen Solutions, Glycotest, Glympse Bio, Gnome Diagnostics, GNS Healthcare, Grace Bio-Labs, Grail, Grand Valley State University, Grunenthal, Guardant Health, Gubra, H3 Biomedicine, HalioDx, Hannover Medical School, Harlan Laboratories, Health Diagnostics Laboratory, Health Sciences Research Institute Germans Trias i Pujol Foundation, Heat Biologics, Hebrew University of Jerusalem, Hennepin County Medical Center, Henry Ford Health System, Hoag Memorial Hospital Presbyterian, Hologic, Horizon 2020, Horizon Discovery, Hoth Therapeutics, HTG Molecular Diagnostics, Human Longevity, Idera Pharmaceuticals, Ignyta, ILiAD Biotechnologies, Illumina, ImaBiotech, Image Analysis, ImaginAb, Imanova, IMIDomics, Immodulon Therapeutics, ImmuDyne, ImmunArray, Immunexpress, ImmunoGen, Immunovia, Imugene, IncellDx, Indica Labs, Indivumed, Innate Pharma, Innovate UK, Innovative Medicines Initiative (IMI), Inova Diagnostics, Inova Health System, Inserm, Inserm Transfert, Insight Genetics, Institut Curie, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Cancer Research, Institut Gustave Roussy, Instituto Valenciano De Oncologia, Institut Pasteur, IntegraGen, Integrated Biobank of Luxembourg, International Progressive MS Alliance, Interpace Diagnostics, Interpace Diagnostics Group, InterpretOmics, Intrinsic LifeSciences, Invectys, inVentiv Health, Invetech, inviCRO, IO Biotech, IPMD, IROA Technologies, IRX Therapeutics, iThera Medical, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, Juventas Therapeutics, Kalgene Pharmaceuticals, Keck Graduate Institute of Applied Life Sciences, Keck School of Medicine of USC, KineMed, Kings College London, Knight Diagnostic Laboratories, Konica Minolta, Kymab, Laboratory Corporation of America, Lantern Pharma, Lantheus Holding, Lee Moffitt Cancer Center, LEO Pharma, LifeOmic, Lipotype, Lucid Diagnostics, Lundbeck, Lupus Foundation of America (LFA), Lysosomal Therapeutics, Mannin Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mayo Clinic, MBio Diagnostics, MC10, McGill University, McMaster University, MD Anderson Cancer Center, MD Biosciences, MDxHealth, MEDIAN Technologies, Medical Prognosis Institute, Medical Research Council, Medical University of Graz, Medical University of Innsbruck, Medical University of South Carolina, Medicinal Genomics, Medicines Discovery Catapult, MediciNova, MedImmune, Melanoma Research Foundation, Memorial Sloan Kettering Cancer Center, Mendel Health, Merck and Co, Merck KGaA, Metabolon, Metanomics Health, Michael J Fox Foundation, Microbiotica, Microsoft, Mikrogen, MiNDERA, Mindstrong Health, Miraculins, Mirnax Biosens, MiRXES, Mitsubishi Tanabe Pharma, MolecularMD, Mologen, Montreal Heart Institute, Moores Cancer Center, Movember Foundation, MRM Proteomics, Multiple Myeloma Research Foundation, Mundipharma, Muscular Dystrophy Association, MyCartis, Myriad RBM, Nancy Lurie Marks Family Foundation, NanoMab Technology, NanoString Technologies, NanoView Biosciences, NASA, National Cancer Institute, National Center for Tumor Diseases, National Healthcare Services (NHS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Science Foundation, NEC, Nektar Therapeutics, Nemucore Medical Innovations, Neogenomics, Neoteryx, Nestle, NetScientific, Neuraltus Pharmaceuticals, NeurExo Sciences, NeuroLex Laboratories, NeuroPointDX, NeuroTrauma, Newcastle University, Newomics, Nightingale Health, NMI TT Pharmaservices, Nordic Bioscience, Northeast ALS Consortium, Northwestern University, Novartis, Nova Southeastern University, Nrgene, Nuclea Biotechnologies, Nucleix, NuGen Technologies, NuMedii, NuView Life Sciences, NxGEN MDx, NX Prenatal, Oklahoma Medical Research Foundation, Olaris, Oligomerix, Olink Bioscience, OmicScouts, Oncgnostics, Oncimmune, Oncimmune Ltd, Oncoceutics, OncoCyte, Oncodesign, OncoGenesis, Oncologie, Oncology Venture, OncoMed Pharmaceuticals, OncoSec Medical, Ontario Cancer Biomarker Network, Ontario Institute for Cancer Research, Optina Diagnostics, Oregon Health Sciences University, Ortho-Clinical Diagnostics, OSE Immunotherapeutics, Oslo University Hospital, Otsuka, Ovid Therapeutics, Owlstone Medical, Oxford Biodynamics, Pacific Biomarkers, Pais Vasco University, Pancreatic Cancer Action Network, Paradigm, Parent Project Muscular Dystrophy, Paris Descartes University, Parkinson's Institute and Clinical Center, PAVmed, PEAR Therapeutics, Pelago Bioscience, Pennsylvania State University, PerkinElmer, Personal Genome Diagnostics, Personalis, PersonalizeDx, PETNET Solutions, Pfizer, Phadia, Pharmaco-Kinesis, PierianDx, PointCross Life Sciences, PPD, Precision for Medicine, PredictImmune, Premas Life Sciences, Prescient Medical, Prestizia, Prevacus, Prism Research, Probiodrug, Procter & Gamble, Profil Institute for Clinical Research, Progenics Pharmaceuticals, Prognos, Prosenex, Prostate Cancer Foundation (PCF), Protagen, Protagonist Therapeutics, Protea Biosciences, Pulmonary Fibrosis Foundation (PFF), Q BioMed, Qiagen, Quadrant Biosciences, Quanterix, Quantum Design International, QuantumDx, Quantum Leap Health Care Collaborative, Quest Diagnostics, Quintiles, R-Biopharm, RayBiotech, RCK, Readout Health, Redx Pharma, Regulus Therapeutics, Renovar, ReproCell, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Research Council of Norway, Research Foundation of State University of New York, Response Genetics, Reveal Biosciences, rEVO Biologics, Rhythm Pharmaceuticals, RiboMed, Ridge Diagnostics, Rosetta Genomics, Royal Philips Electronics, Saladax Biomedical, Sanford Burnham Institute, Sanofi, Sanofi-Pasteur, San Raffaele Hospital, Sarah Cannon Research Institute, Sarepta Therapeutics, Scienion, Sciex, Scripps Research Institute, Second Genome, Sedona Integrative Medical Clinic, Sengenics, Sentinel Oncology, Seven Bridges Genomics, Shanghai Institutes of Preventative Medicine, Sheba Medical Center, Shire Human Genetic Therapies, Siemens, Siemens Healthineers, Sigma-Aldrich, Siloam Biosciences, Singapore Eye Research Institute (SERI), Singlera Genomics, Singulex, Small Business Innovation Research, SomaGenics, SomaLogic, Sony DADC, Sophia Genetics, Soricimed Biopharma, Sphingotec, SQI Diagnostics, SRI International, Stanford University, Stanford University School of Medicine, Stemina Biomarker Discovery, Strain Genie, Strata Oncology, STRATIFYER Molecular Pathology, Stroke Detection Plus, Sunnybrook Health Sciences Centre, SUNY Upstate Medical University, Surrey Cancer Research Institute, Syapse, Synthetic Biologics, Syros Pharmaceuticals, Sysmex Inostics, TaiRx, Takeda Pharmaceutical, Tampere University Hospital, Targos, Tasso, Technology Foundation STW, Tempus, Tetra Discovery Partners, Teva Pharmaceutical Industries, The Cyprus Institute of Neurology and Genetics, The National Football League, The Parker Institute For Cancer Immunotherapy, Theradiag, Theranostics Health, Thermo Fisher Scientific, The Technical University Of Munich, Three Rivers Provider Network, Tiziana Life Sciences, TMRC, Tocagen, Tolero Pharmaceuticals, Tor Vergata University Hospital, Toulouse University Hospital, TRACON Pharmaceuticals, Transgenomic, Translational Genomics Research Institute, Transplant Genomics, TrovaGene, TTFactor, Tymora Analytical Operations, UCF College of Medicine, UK Government, Ultivue, UNICANCER, University Ann & Robert H. Lurie Children’s Hospital, University College London, University of Bristol, University of California, Davis, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Florida, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Minnesota, University of Montreal, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Southampton, University of South Carolina, University of Surrey, University of Tokyo, University of Washington, University Pierre Marie Curie, US Department of Commerce, Vancouver Prostate Centre, Vanderbilt-Ingram Cancer Center, Ventana Medical Systems, Veravas, VerdePharmHealth, Verily, Vigilant Biosciences, Virax, Virginia Polytechnic Institute and State University, Vivante Health, ViveBio, VolitionRX, VU Medical Center, Washington University in St Louis, Waters Corporation, Wearifi, Weill Cornell Medical College, Weston Brain Institute, WinterLight Labs, WuXi NextCODE Genomics, WuXi PharmaTech, Yale School of Medicine, Yale University, Ymir Genomics, Zellkraftwerk, Zionexa

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!